BioCentury
ARTICLE | Clinical News

Unoprostone isopropyl: Completed Phase III enrollment

November 11, 2013 8:00 AM UTC

Sucampo said R-Tech Ueno completed enrollment of 180 patients in a double-blind, placebo-controlled, Japanese Phase III trial evaluating 0.15% unoprostone isopropyl eye drops for 52 weeks. The trial includes a 52-week open-label study following the treatment period. The Japan Science and Technology Agency (Saitama, Japan) is funding the trial through its Adaptable and Seamless Technology Transfer Program through Target-Driven R&D (A-STEP) program (see BioCentury, Feb. 11). ...